Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials.

@article{Boessen2013ComparingHA,
  title={Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials.},
  author={Ruud Boessen and Rolf H. H. Groenwold and Mirjam J. Knol and Diederick E. Grobbee and Kit C. B. Roes},
  journal={Journal of affective disorders},
  year={2013},
  volume={145 3},
  pages={363-9}
}
BACKGROUND The 17-item Hamilton depression rating scale (HAMD(17)) is the standard efficacy outcome in antidepressant clinical trials. It is criticized for multidimensionality and poorly discriminating treatment from placebo. HAMD subscales may overcome these limitations and reduce the sample size of clinical trials. This study compared the discriminative performance of the HAMD(17) and three established HAMD subscales (Bech, Maier-Philipp, Gibbons) across a range of antidepressants with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS